Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma

Nature Genetics

Volumn 47, Issue 10, 2015, Pages 1168-1178

  Moffitt, Richard A ^a   Marayati, Raoud ^a   Flate, Elizabeth L ^a   Volmar, Keith E ^b   Loeza, S Gabriela Herrera ^a   Hoadley, Katherine A ^a,c   Rashid, Naim U ^a   Williams, Lindsay A ^a,d   Eaton, Samuel C ^c   Chung, Alexander H ^c   Smyla, Jadwiga K ^a   Anderson, Judy M ^e   Kim, Hong Jin ^a,c   Bentrem, David J ^f   Talamonti, Mark S ^g   Iacobuzio Donahue, Christine A ^h   Hollingsworth, Michael A ^e   Yeh, Jen Jen ^a,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d IL   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; RNA; TRANSCRIPTION FACTOR GATA 6;

ARTICLE; CELL SURVIVAL; CODON; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENOME; HUMAN; MAJOR CLINICAL STUDY; MALE; MICRODISSECTION; MOUSE; NONHUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREATIC STELLATE CELL; PRIORITY JOURNAL; STROMA; TUMOR CELL LINE; ADENOCARCINOMA; ANIMAL; GENETIC HETEROGENEITY; GENETICS; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; STROMA CELL; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; CARCINOMA, PANCREATIC DUCTAL; FEMALE; GENE EXPRESSION; GENETIC HETEROGENEITY; HETEROGRAFTS; HUMANS; MALE; PANCREATIC NEOPLASMS; STROMAL CELLS;

EID: 84942885357     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3398     Document Type: Article

References (61)

1. Biankin A.V., et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399-405 (2012
2. Jones S., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806 (2008
3. Waddell N., et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495-501 (2015
4. Yachida S., et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117 (2010
5. Collisson E.A., et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17, 500-503 (2011
6. Crnogorac-Jurcevic T., et al. Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 21, 4587-4594 (2002
7. Witkiewicz A.K., et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun. 6, 6744 (2015
8. Iacobuzio-Donahue C.A., et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am. J. Pathol. 162, 1151-1162 (2003
9. Logsdon C.D., et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 63, 2649-2657 (2003
10. Stuart R.O., et al. In silico dissection of cell-type-associated patterns of gene expression in prostate cancer. Proc. Natl. Acad. Sci. USA 101, 615-620 (2004
11. Wang Y., et al. In silico estimates of tissue components in surgical samples based on expression profiling data. Cancer Res. 70, 6448-6455 (2010
12. Yoshihara K., et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013
13. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Campbell P.J., & Stratton M.R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3, 246-259 (2013
14. Alexandrov L.B., et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013
15. Biton A., et al. Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes. Cell Rep. 9, 1235-1245 (2014
16. Stratford J.K., et al. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med. 7, e1000307 (2010
17. Whitfield M.L., et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol. Biol. Cell 13, 1977-2000 (2002
18. Froeling F.E., et al. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression. Gastroenterology 141, 1486-1497 (2011
19. Özdemir B.C., et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719-734 (2014
20. Rhim A.D., et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25, 735-747 (2014
21. Lee J.J., et al. Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proc. Natl. Acad. Sci. USA 111, E3091-E3100 (2014
22. Olive K.P., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461 (2009
23. Erkan M., et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin. Gastroenterol. Hepatol. 6, 1155-1161 (2008
24. Cohen S.J., et al. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas 37, 154-158 (2008
25. Hwang R.F., et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 68, 918-926 (2008
26. Vonlaufen A., et al. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res. 68, 2085-2093 (2008
27. Herrera M., et al. Functional heterogeneity of cancer-associated fibroblasts from human colon tumors shows specific prognostic gene expression signature. Clin. Cancer Res. 19, 5914-5926 (2013
28. Nones K., et al. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Int. J. Cancer 135, 1110-1118 (2014
29. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315-322 (2014
30. Damrauer J.S., et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc. Natl. Acad. Sci. USA 111, 3110-3115 (2014
31. McConkey D.J., Choi W., & Dinney C.P. New insights into subtypes of invasive bladder cancer: considerations of the clinician. Eur. Urol. 67, e76-e78 (2015
32. Parker J.S., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160-1167 (2009
33. Prat A., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12, R68 (2010
34. Tibshirani R., Hastie T., Narasimhan B., & Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl. Acad. Sci. USA 99, 6567-6572 (2002
35. Isella C., et al. Stromal contribution to the colorectal cancer transcriptome. Nat. Genet. 47, 312-319 (2015
36. Rubio-Viqueira B., et al. An in vivo platform for translational drug development in pancreatic cancer. Clin. Cancer Res. 12, 4652-4661 (2006
37. Stolze B., Reinhart S., Bulllinger L., Fröhling S., & Scholl C. Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines. Sci. Rep. 5, 8535 (2015
38. Ihle N.T., et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J. Natl. Cancer Inst. 104, 228-239 (2012
39. Carey L., Winer E., Viale G., Cameron D., & Gianni L. Triple-negative breast cancer: disease entity or title of convenience?. Nat. Rev. Clin. Oncol. 7, 683-692 (2010
40. Bardeesy N., et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 20, 3130-3146 (2006
41. Haeger S.M., et al. Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors. Oncogene doi: 10.1038/onc.2015.112 (20 April 2015
42. Garrido-Laguna I., et al. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin. Cancer Res. 17, 5793-5800 (2011
43. Dal Molin M., et al. Very long-term survival following resection for pancreatic cancer is not explained by commonly mutated genes: results of whole-exome sequencing analysis. Clin. Cancer Res. 21, 1944-1950 (2015
44. Zhang Y., et al. A Gata6-Wnt pathway required for epithelial stem cell development and airway regeneration. Nat. Genet. 40, 862-870 (2008
45. Zhong Y., et al. GATA6 activates Wnt signaling in pancreatic cancer by negatively regulating the Wnt antagonist Dickkopf-1. PLoS ONE 6, e22129 (2011
46. Wamunyokoli F.W., et al. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin. Cancer Res. 12, 690-700 (2006
47. Ji H., et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 448, 807-810 (2007
48. Croft D., et al. The Reactome pathway knowledgebase. Nucleic Acids Res. 42, D472-D477 (2014
49. Ashburner M., et al. Gene Ontology: tool for the unification of biology. Nat. Genet. 25, 25-29 (2000
50. Bild A.H., et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353-357 (2006
51. Nishimura D. BioCarta. Biotech. Software Internet Rep. 2, 117-120 (2001
52. Shi L., et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat. Biotechnol. 28, 827-838 (2010
53. Hoadley K.A., et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158, 929-944 (2014
54. Iacobuzio-Donahue C.A., et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J. Clin. Oncol. 27, 1806-1813 (2009
55. Subramanian A., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005
56. Neel N.F., et al. Response to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation. Mol. Cancer Ther. 13, 122-133 (2014
57. Bachem M.G., et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128, 907-921 (2005
58. Conway T., et al. Xenome - A tool for classifying reads from xenograft samples. Bioinformatics 28, i172-i178 (2012
59. Kim D., et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013
60. Trapnell C., et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7, 562-578 (2012
61. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012